<table>
<thead>
<tr>
<th></th>
<th>Table of Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Presidential report</td>
</tr>
<tr>
<td>2</td>
<td>Secretary-General’s report</td>
</tr>
<tr>
<td>3</td>
<td>Vice-presidents’ reports</td>
</tr>
<tr>
<td>4</td>
<td>Treasurer’s report</td>
</tr>
<tr>
<td>5</td>
<td>Election of Executive Committee 2017-2019</td>
</tr>
<tr>
<td>6</td>
<td>Presidential Programme 2017-2019</td>
</tr>
<tr>
<td>7</td>
<td>Any other business</td>
</tr>
</tbody>
</table>
Presidential report
Innovative approach
Strategy 2015-2017

Building a **platform** to enhance EAACI’s profile as an attractive partner for EU bodies, relevant companies and future members

1. **Scientific output** – Guidelines
2. **Scientific Dissemination** : EAACI journals and books
3. **Membership**
4. **Governance project**
5. **Scientific vision**: precision medicine & precision health
6. **EU outreach**

**Ensuring financial stability and viability**
1 - Best Practice Guidelines

Food Allergy and Anaphylaxis Guidelines for Clinical Practice

ALLERGEN IMMUNOTHERAPY GUIDELINES FOR CLINICAL PRACTICE
June, 2017- October 2017

• Will support health care professionals’ use of AIT
• Will highlight benefits at public and policy maker levels
• Will promote health economics of AIT
1 – NEW Guidelines Committee

AIM: oversee the successful generation of new guidelines

- Will support getting appraisal of evidence – SR
- Will provide internal training
- Will facilitate collaborative projects as new guidelines
- Will design and support implementation
Clinical and Translational Allergy
NEW Impact factor 3.23
EAACI Membership : 10,000
Young Organization

- Under 36: 46%
- Between 36-60: 45%
- Over 60: 9%
EAACI Membership Profile

- Male: 46%
- Female: 58%

42%
3 - Initiatives for Membership

- Nurturing Future Leaders
- Leadership Course
- Talent Development Course for Juniors
- 4th Women in Science Symposium
- Nurturing Senior leaders: Master Class model, Hands-on Courses

Vienna 2016, Helsinki, 2017

Copenhagen 2014--Helsinki 2017
INTEGRATED APPROACH (i)

Joining forces in building strong alliances

- National Allergy Societies Committee: 54
- International Societies Council: 16
- Patient’s organization committee: 28
INTEGRATED APPROACH (ii)

Joining forces in building strong alliances

Increased projects with Sister Societies:
- AAAAI, ERS, APAPARI, APAACI, WAO

Outreach to Primary care: UEMO

Collaboration for advocacy with Industry partners
Governance project

- NEW Structure in place: pilot phase of 2 years
- NEW Governance Committee: supervising on-going process
- Revision of the Constitution: to be circulated to the membership
- Revision of the Bylaws: on-going
- Promoting efficiency and governance at the Headquarters
5- Scientific Vision

Precision Medicine in Allergy

Practall: 1- Asthma, Rhinitis and Atopic Dermatitis
2- Food allergy, anaphylaxis, drug allergy

• Personalized care
• Prediction of success
• Prevention (prim/sec/tert)
• Participation of patient

APPLICABLE TO
ALLERGIES & AIRWAYS DISEASES

Networks of Centres

• Facilitating implementation of best standards of practice
• Allergy Comprehensive Centres
6. EU Outreach
Advocacy Platform

EU Liaison Office

Strong alliances: National Societies & Patient Organisations

Policy events of the MEP Interest Group in EU Parliament

Launch CALL TO ACTION April 26th

High Level EU Business lunch at the Annual Congress June 19
A POLITICAL CALL TO ACTION IN EUROPE

Key stakeholders joining hands to initiate the Call and promote its endorsement campaign

**Policymakers**
European Parliament
Interest Group on Allergy and Asthma

**Healthcare Professionals**

**Patients**

- To European Member States
- To European Commission
- To European Parliament
- To patients, healthcare stakeholders, and civil society
UNITED ACTION FOR ALLERGY AND ASTHMA

www.CallAllergyAsthma.eu – by September 30th

CLICK TO SIGN AS

- POLICY MAKERS
  Individuals working in an EU institution (e.g. European Commission, Parliament, Council), or in a national government or administration (e.g. Ministry of health, public health institute, others).

- ORGANISATION
  Non-profit organisation active in a relevant field (e.g. patients organisations, civil society and consumer organisations, medical associations, health and environment NGOs, healthcare trade associations).

- INDIVIDUAL
  Citizen supporter of the cause and signing in his/her own name.
Ensuring financial sustainability

- Prioritization of projects according to the strategic priorities
- Regular Strategic meetings with industry partners
- 2 NEW Founder Sponsors: PLATINUM
- 1 NEW Founder sponsor: GOLD
- Ensuring development of flagships focused meetings and overall no budget deficit for meetings
- Ensuring transparency in accounting
Thank you for your trust
Approval

of the Presidential Report
Secretary-General’s report
Internal Affairs

➢ New Governance Model
  ➢ Organisational structure
  ➢ Roles and responsibilities

➢ Revision of the Constitution and Bylaws
EAACI Organisational Structure

**Sections (6)**
- Basic & Clinical Immunology
- Asthma
- Pediatric
- Dermatology
- ENT
- Junior Members Assembly

**Interests Groups (6)**
- Food Allergy
- Drug Allergy
- Allergen Immunotherapy
- Environmental & Occupational Allergy
- Allergy Diagnosis & Systems Medicine
- IG Allied Health & Primary Care

**Working Groups**
- WG on Immunodeficiencies
- WG on Infections
- WG on Biologicals
- WG on Allergy, Asthma & Sports
- WG on Ocular Allergy
- WG on Food Allergy
- WG on Eosinophilic Esophagitis
- WG on Insect Venom Hypersensitivity
- WG on Epidemiology
- WG on Aerobiology and Pollution
- WG on Genomics and Proteomics
- WG on Comparative Veterinary Allergology
- WG on Allied Health
- WG on Primary Care
EAACI HQ - Organisation Headquarters

Sue C. C. Paredi
Haris Kostaras
Lena Geltenbort-Rost
Veronika Topolska

Jeanette Kobler
Katerina Klimogianni
Charlotte Horder
Enna Heller

Isabel Heitmeyer
Kendra Zuber
Francesca Spinedi
Approval

of the Secretary General’s Report
Vice-presidents’ reports
Vice-president Congresses
### Facts and Figures

<table>
<thead>
<tr>
<th>Year</th>
<th>Congress</th>
<th>Total Attendees</th>
<th>Abstracts</th>
<th>Late Breaking Abstracts</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>Istanbul</td>
<td>7,874</td>
<td>1,886</td>
<td>264</td>
<td>2,150</td>
</tr>
<tr>
<td>2012</td>
<td>Geneva</td>
<td>6,217</td>
<td>1,717</td>
<td>270</td>
<td>1,987</td>
</tr>
<tr>
<td>2013</td>
<td>Milan</td>
<td>7,696</td>
<td>1,678</td>
<td>290</td>
<td>1,968</td>
</tr>
<tr>
<td>2014</td>
<td>Copenhagen</td>
<td>7,403</td>
<td>1,429</td>
<td>438</td>
<td>1,867</td>
</tr>
<tr>
<td>2015</td>
<td>Barcelona</td>
<td>7,667</td>
<td>1,520</td>
<td>330</td>
<td>1,850</td>
</tr>
<tr>
<td>2016</td>
<td>Vienna</td>
<td>7,791</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Helsinki</td>
<td>7,997</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Abstracts

In order to improve the quality of Thematic Poster Sessions (TPS), EAACI has decided to invest into the Interactio App, which can be used on delegates’ own mobile device for acoustically clear listening of Thematic Poster Presentations.
CME Credits & Technology used at EAACI (Waytation)

Scan-free automated certification process at the EAACI 2017 congress
Provider of digital solution is company Waytation

3 simple steps on how to automatically collect your CME credits with EAACI CME:

1) Collect your lanyard (with badge) in the registration area
2) Pick up your tag (chip) at the CME Counter and synchronize it with your badge
3) Attend EAACI Scientific Sessions each day and collect your CME credits automatically

Advantages:

✓ No more hand scanning of badges in front of each session room
✓ Additionally, it enables each participant to receive an overview of each session they personally attended
✓ EAACI will gain valuable insights about the congress programme and exhibition; This will allow the Scientific Programme Committee to constantly improve future EAACI congresses and to recognise popular topics amongst all attendees
EAACI Congress 2018: Munich

26 – 30 May 2018 - ICM Messe München

**Time line**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker invitations (PL, SYM, WS, PG, LL, P&amp;C)</td>
<td>July / August 2017</td>
</tr>
<tr>
<td>Scientific Programme and Registration online</td>
<td>25 October 2017</td>
</tr>
<tr>
<td>Chair Invitations (PL, SYM, WS, PG, LL, P&amp;C)</td>
<td>begin October 2017</td>
</tr>
<tr>
<td>Start Abstract Submission</td>
<td>23 October 2017</td>
</tr>
<tr>
<td>Deadline for Abstract Submission</td>
<td>15 January 2018</td>
</tr>
<tr>
<td>Late-breaking abstract submission</td>
<td>15 - 28 February 2018</td>
</tr>
<tr>
<td>Meetings</td>
<td>Marathon Meeting</td>
</tr>
<tr>
<td></td>
<td>16-17 February</td>
</tr>
</tbody>
</table>

Congress Local Chair: Carsten Schmidt-Weber, SPC- coordinator: Susanne Halken

Contract with the venue has been finalized
Past Focused Meetings 2016

FAAM 2016

13 – 15 October 2016 – Rome, Italy
- Attendees: 1,117
- Accepted abstracts: 270  (*presented: oral 17, posters 253*)
- Countries: 63

ISAF 2016

17 – 19 November 2016 – Manchester, UK
- Attendees: 252
- Accepted abstracts: 50  (*presented oral: 9, posters 32*)
- Countries: 36
Past Focused Meetings 2017

SERIN 2017

30 March – 1 April 2017 – Düsseldorf, Germany
- Attendees: 115
- Accepted abstracts: 39  *(presented: oral 13, posters 18)*
- Countries: 63

SAM 2017

27 – 29 April 2017 – Zurich, Switzerland
- Attendees: 261
- Accepted abstracts: 45  *(presented oral: 15, posters 37)*
- Countries: 42
Upcoming Focused Meetings 2017

PAAM 2017

26 – 28 October 2017 – London, UK
Chairs: George du Toit, UK and Montserrat Alvaro Lozano, ES

ISMA 2017

9 – 11 November 2017 – Luxembourg
Chair: Makurs Ollert, Lux
Upcoming Focused Meetings 2018

**DHM 2018**

19 – 21 April 2018 – Amsterdam, the Netherlands  
Chairs: Ingrid Terreehorst, NL, Maria J. Torres, ES  
and Knut Brockow, DE

**FAAM 2018**

18 – 20 October 2018 – Copenhagen, Denmark  
Chairs: Carsten Bindslev-Jensen, DK and Lars K. Poulsen, DK
Vice-president Education & Specialty
## Allergy Schools and Master Classes: Completed 2016-2017

<table>
<thead>
<tr>
<th>Allergy Schools / Master Classes - Completed</th>
<th>Date</th>
<th>Registered Participants</th>
<th>Accepted Abstracts</th>
<th>Speakers</th>
<th>CME Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy School on Drug Allergy in Children, Belgrade, Serbia</td>
<td>22-24 September 2016</td>
<td>87</td>
<td>22</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Master Class on Translational Immunology in Allergic Diseases, Zurich, Switzerland</td>
<td>21-22 October 2016</td>
<td>45</td>
<td>N/A</td>
<td>19</td>
<td>9</td>
</tr>
<tr>
<td>Winter School on Basic Immunology Research in Allergy and Clinical Immunology, Sierra Nevada, Spain</td>
<td>26-29 January 2017</td>
<td>72</td>
<td>67</td>
<td>6 + Section board</td>
<td>16</td>
</tr>
<tr>
<td>Allergy School on Eosinophilic Esophagitis, Rotterdam-Vlaardingen, The Netherlands</td>
<td>16-18 March 2017</td>
<td>87 (max)</td>
<td>17</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>Master Class on Primary Immunodeficiencies, Prague, Czech Republic</td>
<td>7 - 8 April 2017</td>
<td>49 (max)</td>
<td>6 case reports</td>
<td>11</td>
<td>8</td>
</tr>
</tbody>
</table>
## Allergy Schools and Master Classes: Upcoming 2017-2018

<table>
<thead>
<tr>
<th>Allergy Schools / Master Classes - Upcoming</th>
<th>Date</th>
<th>Speaker invitations</th>
<th>Event publicised</th>
<th>Registrations</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food Allergy Training Course “Prevention and Treatment of Food Allergy”, Manchester, United Kingdom</td>
<td>14-16 September 2017</td>
<td>20.03.2017</td>
<td>17.03.2017</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Winter School on Basic Immunology Research in Allergy and Clinical Immunology, Saas-Fee, Switzerland</td>
<td>25-28 January 2018</td>
<td>26.04.2017</td>
<td>22.05.2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergy School on Aerobiology and Pollution, Dubrovnik, Croatia</td>
<td>15-17 March 2018</td>
<td>30.07.2017</td>
<td>30.07.3017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Master Class on Occupational Allergy, Madrid, Spain</td>
<td>29-30 September 2017</td>
<td>23.03.2017</td>
<td>31.03.2017</td>
<td>9</td>
<td>N/A</td>
</tr>
<tr>
<td>Master Class on Biologicals, Prague, Czech Republic</td>
<td>13-14 April 2018</td>
<td>02.06.2017</td>
<td>08.06.2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Master Class on Practical Allergy Diagnostics, Ebsdorfergrund, Germany</td>
<td>23-24 March 2018</td>
<td>15.07.2017</td>
<td>15.07.2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EAACI/UEMS Knowledge Examination</td>
<td>Vienna Congress, 2016</td>
<td>Helsinki Congress, 2017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------</td>
<td>-----------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of Applications</td>
<td>56</td>
<td>68</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of EAACI members</td>
<td>50</td>
<td>65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of Non-Members</td>
<td>6</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of European Countries</td>
<td>15</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of Non-European Countries</td>
<td>7</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(South Africa, Mexico, Russia, Thailand, Japan, India, Turkey)</td>
<td>(Argentina, South Africa, Iran, India, Turkey, Russia, Saudi Arabia, Paraguay, Sri Lanka, Namibia, Jordan, Egypt, Chile, Canada and Brazil)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of Actual Registrations (paid)</td>
<td>50</td>
<td>61</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Requested and Received UEMS Financial Support</td>
<td>15</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The roadmap for Allergology in Europe

• EAACI Taskforce on subspecialties of Allergology
• EAACI Taskforce on allergy services in Europe
• SWOT analysis
• European Training requirements (ETR) for the specialty of Allergology

Roy Gerth van Wijk
EAACI Task Force on subspecialties of Allergology

Full specialty of allergology:
Bulgaria, Croatia, Cyprus, Czech Republic, France, Great Britain, Greece, Italy, Lithuania, Luxemburg, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland

Subspeciality of allergology:
Estonia, Finland, Germany, Hungary, Netherlands, Turkey.

No subspecialty or full specialty:
Belgium, Denmark, Ireland, Austria, Slovenia.
Total number of specialists
Countries with combined Allergology & Clin Imm
• Faster accreditation process
• Maximum of 8 ECMEC’s per day
• Accreditation of
  • e-Learning Modules (ELM)
  • e-platform (at least 10 ELMs)
  • Educational App
  • Educational e-Library
EAACI Allergen Immunotherapy Guidelines

Chair: Antonella Muraro

- Asthma
- Rhinoconjunctivitis
- Prevention
- Venom
- Food allergy
- Primary care
- Regulatory
## Nomination of CME and Exam Committee Chairs 2017-19

<table>
<thead>
<tr>
<th>Exam Committee Chairperson</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Khaitov, Musa R.</td>
<td>Exam Committee Chair</td>
</tr>
<tr>
<td>Czarnecka-Operacz, Magdalena</td>
<td>CME Committee Chair</td>
</tr>
</tbody>
</table>
New educational tools: perspectives

- Webinars
- Hybrid meetings
- Exam preparation (Online)
- Online courses (Target audience)
Vice-president
Communication and Membership
EAACI journals – Allergy and PAI

New contract with Wiley 2017-2020
- Co-ownership
- Significant increase in revenue (6X)

Open Call for Editors
EAACI journals – Clinical and Translational Allergy (CTA)

Many congratulations for the IF

Ongoing negotiations with the publisher (BMC)

• Immediate ownership
• Sharing resources (editors fee, secretarial support)
• Revised marketing strategy
### Membership Report - Number of active members – 2017 (May)

<table>
<thead>
<tr>
<th>Year (May)</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>2921</td>
</tr>
<tr>
<td>2002</td>
<td>3478</td>
</tr>
<tr>
<td>2003</td>
<td>3873</td>
</tr>
<tr>
<td>2004</td>
<td>4206</td>
</tr>
<tr>
<td>2005</td>
<td>4466</td>
</tr>
<tr>
<td>2006</td>
<td>4786</td>
</tr>
<tr>
<td>2007</td>
<td>5103</td>
</tr>
<tr>
<td>2008</td>
<td>5300</td>
</tr>
<tr>
<td>2009</td>
<td>5373</td>
</tr>
<tr>
<td>2010</td>
<td>5868</td>
</tr>
<tr>
<td>2011</td>
<td>6646</td>
</tr>
<tr>
<td>2012</td>
<td>7401</td>
</tr>
<tr>
<td>2013</td>
<td>7489</td>
</tr>
<tr>
<td>2014</td>
<td>8056</td>
</tr>
<tr>
<td>2015</td>
<td>9101</td>
</tr>
<tr>
<td>2016</td>
<td>9326</td>
</tr>
<tr>
<td>2017</td>
<td>10258</td>
</tr>
</tbody>
</table>
Membership Report - Members in good standing

2014: 6710
2015: 7241
2016: 7328
2017 (May): 7165
Gender and age distribution

- **58% Male**
- **42% Female**

**Age Distribution (%)**:
- <25: 2%
- 25-30: 18%
- 31-35: 26%
- 36-45: 25%
- 46-50: 7%
- 51-60: 9%
- Junior Members: 13%

**Junior Members (46%)**
64 National Societies

- WG Specialty:
- WG Health Economics
- WG Guidelines
- WG EU Lobbying
Books

Launch of the AIT Guidelines Part 1

188 pages systematic reviews in
• Prevention of allergy
• Venom immunotherapy
• IgE-food allergy
• Asthma
• Rhinoconjunctivitis
Communication Platforms
Newsletter Timetable 2015-2017

EAACI Congress 2015 in Barcelona: All You Want to Know About Allergy

The Future of Nanoparticles for Diagnostics and Therapy

60 Years of EAACI: A Political Call to Action

EAACI Congress 2016: Great Success in Vienna

EAACI Celebrates 60 Years of Excellence

60th Anniversary EAACI 1956-2016

Priority of Allergic Diseases at European and National Level

EAACI Newsletter Timetable 2015-2017
Approval of the Vice-Presidents’ Reports
Treasurer’s report
<table>
<thead>
<tr>
<th>'000 €</th>
<th>as of 31.12.</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2016</td>
<td>3'853.0</td>
</tr>
<tr>
<td>December 2015</td>
<td>3'790.5</td>
</tr>
<tr>
<td>December 2014</td>
<td>3'994.1</td>
</tr>
<tr>
<td>December 2013</td>
<td>2'862.4</td>
</tr>
<tr>
<td>December 2012</td>
<td>3'247.3</td>
</tr>
<tr>
<td>December 2011</td>
<td>3'192.2</td>
</tr>
<tr>
<td>December 2010</td>
<td>2'677.3</td>
</tr>
<tr>
<td>December 2009</td>
<td>2'658.8</td>
</tr>
<tr>
<td>December 2008</td>
<td>2'270.0</td>
</tr>
</tbody>
</table>

| Capital as of 31.12.2015 | 3'790.5 |
| Profit 2016 prior ZKB | 106.6 |
| Adjustment ZKB invest | -44.1 |
| New capital as of 31.12.2016 | 3'853.0 |
Capital invested at ZKB
development of Market Value

<table>
<thead>
<tr>
<th>Year</th>
<th>Nominal Capital</th>
<th>Market Value at End of Year</th>
<th>Interest received</th>
<th>Interest received (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>2310</td>
<td>2,477</td>
<td>80.7</td>
<td>3.49%</td>
</tr>
<tr>
<td>2012</td>
<td>2550</td>
<td>2,797</td>
<td>101.1</td>
<td>3.96%</td>
</tr>
<tr>
<td>2013</td>
<td>2950</td>
<td>3,251</td>
<td>116.7</td>
<td>3.96%</td>
</tr>
<tr>
<td>2014</td>
<td>2950</td>
<td>3,325</td>
<td>115.4</td>
<td>3.91%</td>
</tr>
<tr>
<td>2015</td>
<td>3040</td>
<td>3,193</td>
<td>106.8</td>
<td>3.51%</td>
</tr>
<tr>
<td>2016</td>
<td>3110</td>
<td>3,314</td>
<td>111.7</td>
<td>3.59%</td>
</tr>
</tbody>
</table>
### Statement 2016 - Summary

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Income</strong></td>
<td>4'450'303</td>
<td>4'332'800</td>
</tr>
<tr>
<td><strong>Total Expenditures</strong></td>
<td>4'343'739</td>
<td>4'975'820</td>
</tr>
<tr>
<td>projects on hold</td>
<td>0</td>
<td>82'300</td>
</tr>
<tr>
<td>Adjustment ZKB investment to market value</td>
<td>-44'116</td>
<td>0</td>
</tr>
<tr>
<td><strong>+Surplus/-Deficit</strong></td>
<td>62'448</td>
<td>-725'320</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td>Statement December</td>
<td>Budget 2016 adj. Approved ExCom June 2016</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>--------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Membership Subscription</td>
<td>309'900</td>
<td>320'000</td>
</tr>
<tr>
<td>Income from Founder Sponsor Members</td>
<td>1'911'100</td>
<td>1'805'800</td>
</tr>
<tr>
<td>Income from Corporate Sponsor</td>
<td>80'000</td>
<td>80'000</td>
</tr>
<tr>
<td>Fundraising</td>
<td>45'194</td>
<td>50'000</td>
</tr>
<tr>
<td>Congresses</td>
<td>1'300'000</td>
<td>1'400'000</td>
</tr>
<tr>
<td>Focussed Meetings</td>
<td>169'759</td>
<td>90'000</td>
</tr>
<tr>
<td>Education group</td>
<td>20'238</td>
<td>19'000</td>
</tr>
<tr>
<td>Communication group</td>
<td>66'971</td>
<td>145'000</td>
</tr>
<tr>
<td>Other Income</td>
<td>59'500</td>
<td>30'000</td>
</tr>
<tr>
<td>Interest / Currency</td>
<td>111'720</td>
<td>93'000</td>
</tr>
<tr>
<td>Extraordinary Income</td>
<td>375'921</td>
<td>300'000</td>
</tr>
</tbody>
</table>
Statement 2016 - Expenses  
as of December 31st

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Expenditures</td>
<td>4'343'739</td>
<td>4'975'820</td>
</tr>
<tr>
<td>Total Congresses</td>
<td>39'390</td>
<td>40'000</td>
</tr>
<tr>
<td>Total Task forces/New Projects</td>
<td>718'521</td>
<td>1'147'430</td>
</tr>
<tr>
<td>Total support of External Events</td>
<td>34'467</td>
<td>0</td>
</tr>
<tr>
<td>Total Communications &amp; Membership</td>
<td>610'085</td>
<td>768'050</td>
</tr>
<tr>
<td>Total Education Group</td>
<td>381'952</td>
<td>578'100</td>
</tr>
<tr>
<td>Total External Strategic Activities</td>
<td>178'919</td>
<td>135'000</td>
</tr>
<tr>
<td>Total Administration and ExCom</td>
<td>585'904</td>
<td>623'500</td>
</tr>
<tr>
<td>Total Headquarter</td>
<td>1'373'185</td>
<td>1'519'840</td>
</tr>
<tr>
<td>Total Organisation Growth &amp; Other</td>
<td>109'389</td>
<td>113'900</td>
</tr>
<tr>
<td>Total Contingency</td>
<td>311'926</td>
<td>50'000</td>
</tr>
</tbody>
</table>
### Development Surplus & Deficit

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Income</th>
<th>Total Expenses</th>
<th>Surplus/-Deficit</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>2,415.4</td>
<td>2,085.7</td>
<td>329.7</td>
</tr>
<tr>
<td>2009</td>
<td>2,955.7</td>
<td>2,567.0</td>
<td>388.7</td>
</tr>
<tr>
<td>2010</td>
<td>3,548.9</td>
<td>3,431.3</td>
<td>117.6</td>
</tr>
<tr>
<td>2011</td>
<td>3,682.8</td>
<td>3,167.8</td>
<td>515.0</td>
</tr>
<tr>
<td>2012</td>
<td>3,091.8</td>
<td>3,036.7</td>
<td>55.1</td>
</tr>
<tr>
<td>2013</td>
<td>3,106.3</td>
<td>3,414.6</td>
<td>308.3</td>
</tr>
<tr>
<td>2014</td>
<td>3,784.0</td>
<td>2,726.7</td>
<td>1,057.4</td>
</tr>
<tr>
<td>2015</td>
<td>4,227.5</td>
<td>4,202.7</td>
<td>24.8</td>
</tr>
<tr>
<td>2016</td>
<td>4,450.3</td>
<td>4,343.7</td>
<td>106.6</td>
</tr>
</tbody>
</table>
Audit Report as of 26th April, 2017

European Academy of Allergy and Clinical Immunology, 2016

As monetary auditors, we have audited the financial statements, balance sheet and income statement of European Academy of Allergy and Clinical Immunology for the year ended 31 December 2016.

These financial statements (balance sheet and income statement) are the responsibility of the Board of Directors.

Our responsibility is to express an opinion on these financial statements based on our audit. Our audit was conducted in accordance with auditing standards set forth by the Public Company, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. The audit included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. We have also assessed the accounting policies and significant estimates made and the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the accounting policies and financial statements (balance sheet and income statement) are prepared in accordance with IFRS 2017.
Approval of the Treasurer’s Report
Election of Executive Committee 2017-2019
<table>
<thead>
<tr>
<th>EAACI Role</th>
<th>Name</th>
<th>Lastname</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair, Asthma Section</td>
<td>Zuzana</td>
<td>Diamant</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Chair, Dermatology Section</td>
<td>Knut</td>
<td>Brockow</td>
<td>Germany</td>
</tr>
<tr>
<td>Chair, ENT Section</td>
<td>Philippe</td>
<td>Gevaert</td>
<td>Belgium</td>
</tr>
<tr>
<td>Chair, Basic &amp; Clinical Immunology Section</td>
<td>Jürgen</td>
<td>Schwarze</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chair, Pediatrics Section</td>
<td>Montserrat</td>
<td>Alvaro Lozano</td>
<td>Spain</td>
</tr>
<tr>
<td>Chair, JM Assembly</td>
<td>Ibon</td>
<td>Eguiluz-Gracia</td>
<td>Spain</td>
</tr>
<tr>
<td>Interest Group Representative</td>
<td>Oliver</td>
<td>Pfaar</td>
<td>Germany</td>
</tr>
<tr>
<td>Interest Group Representative</td>
<td>Maria</td>
<td>Torres</td>
<td>Spain</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Antti</td>
<td>Lauerma</td>
<td>Finland</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Isabel</td>
<td>Skypala</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Stefano</td>
<td>Del Giacco</td>
<td>Italy</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Jose Maria</td>
<td>Olaguibel</td>
<td>Spain</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Liam</td>
<td>O’Mahony</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Susanne</td>
<td>Lau</td>
<td>Germany</td>
</tr>
</tbody>
</table>
Presidential Programme
2017-2019
EAACI is leading the way towards a sustainable management programme for allergy and asthma ensuring better health and outcomes at a lower cost
My vision for EAACI

World’s Leading Organisation in Allergy, Asthma and Clinical Immunology

Primary professional platform and family and the for all its members and partners

Train, mentor and engage the next generation of clinicians, researchers and future leaders by setting the value of membership

Strategic Programme 2017-2019
1. Connect science with the transformation of care
   - Solid infrastructure conveying EAACI resources
   - Leadership in research, training and innovation

2. Meet the changing educational needs of our members and stakeholders
   Deliver purposeful education

3. Build the membership value, ownership, and engagement
   Increase recognition of the value of the specialty

4. Grow in a sustainable way
   Organisational Effectiveness

My vision

The goal is to go further and do better
The goal is to go further and do better

Fundamental and applied research in the context of real-world problems

Purposeful education

Allergy Speciality as a career choice

Organisational Effectiveness

Communicating to engage

Optimised financial system

6 innovative key points

Strategic Programme 2017-2019
1. Fundamental and applied research in the context of real-world problems

A. EAACI White Paper on Research, Innovation and Quality Care

1. Standards, Guidance and Training. Quality criteria
   a) Patient care
   b) Allergy Practice and Research

2. Identify and promote research priorities

B. EAACI Scientific Output road-map

C. Data sharing
   Mobile Health
   Allergy 2.0 and 3.0
1. Fundamental and applied research in the context of real-world problems

New structures

Vice-President Science

i. EAACI Scientific Output Committee
ii. Research and Training Committee
iii. Scientific Communication Editor
## 2. Purposeful education

**W. Irving:** "Great minds have purposes, others have wishes."

### Innovative educational portfolio

1. Professional and career development
   - a) Clinical track
   - b) Research track
2. Leadership skills

### New tools

1. Customised programmes
   - medical students
   - patients
   - general public
2. Open source educational content (Allerpedia)

### Address the shortage of allergy specialists globally by improving HCP competence

Multidisciplinary Learner Program for Allergy and Asthma

---

*Strategic Programme 2017-2019*
2. Purposeful education

W. Irving: "Great minds have purposes, others have wishes."

New structures

Tailored Educational Programme Committee

Coordinating input from all stakeholders

The goal is to go further and do better
3. Allergy speciality as a career choice

The welfare of the Academy depends on recruiting young members into the organization and support their lifelong involvement.

Health economics data

Input from:
NAS National Healthcare representatives

EAACI marketing and operational long-term plan to promote Allergy Speciality

Business case

Convince key stakeholders to include allergists in the model of care

Strategic Programme 2017-2019
### 4. Communicating to engage

<table>
<thead>
<tr>
<th>Unique selling proposition for the EAACI brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dedicated to allergy science, committed to your health</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EAACI as an individual membership society</th>
</tr>
</thead>
<tbody>
<tr>
<td>My membership, my EAACI</td>
</tr>
<tr>
<td>My Annual Meeting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strong and persistent focus on advocacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>EAACI is the leading voice in shaping public policies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Respect for diversity and equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EAACI as an open community</td>
</tr>
</tbody>
</table>

---

**Strategic Programme 2017-2019**

*The goal is to go further and do better*
The goal is to go further and do better

4. Communicating to engage

New structures

Annual strategic forum for high level dialogue with stakeholders
5. Organisational Effectiveness

- **Structure**
  - Governance
  - Strong code of Ethics

- **Procedures**

- **Human resources**

**Organisational culture**

- Knowledge
- Professionalism
- Innovation
- Integrity
- Inclusiveness
- Transparency

- Members driven society
- My EAACI

- Value of the speciality
- Excellence in patient care

Reinforce EAACI core values

Strategic Programme 2017-2019

The goal is to go further and do better
6. Optimised financial system

| Constant evaluation of investments and readjustment according to measured value |
| Diversify income streams |
| Long term financial perspective |
| Strengthen EAACI financial responsibility and transparency |
The goal is to go further and do better

Key deliverables

- EAACI White Paper on Research, Innovation and Quality Care
- EAACI Scientific Output Roadmap
- Innovative educational portfolio
- Marketing and operational plan to promote Allergy Speciality
- “My membership. My EAACI” and “My Annual Meeting” programmes
- Optimised financing system and organisational effectiveness
The goal is to go further and do better
Any other Business?
<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair, Ethics Committee</td>
<td>Anthony</td>
<td>Frew</td>
</tr>
<tr>
<td>Chair, CME Committee</td>
<td>Czarnecka-Operacz</td>
<td>Magdalena</td>
</tr>
<tr>
<td>Chair, Knowledge Exam</td>
<td>Musa</td>
<td>Khaitov</td>
</tr>
<tr>
<td>Chair, Specialty Committee</td>
<td>Roy</td>
<td>Gerth van Wijk</td>
</tr>
<tr>
<td>Chair, Patients Organisations Committee</td>
<td>Frans</td>
<td>Timmermans</td>
</tr>
<tr>
<td>Chair, National Allergies Society Committee</td>
<td>M. Beatrice</td>
<td>Bilo</td>
</tr>
<tr>
<td>SPC Coordinator</td>
<td>Susanne</td>
<td>Halken</td>
</tr>
<tr>
<td>Website Editor</td>
<td>Sylwia</td>
<td>Smolinska</td>
</tr>
<tr>
<td>Social Media Editor</td>
<td>Olympia</td>
<td>Tsilochristou</td>
</tr>
</tbody>
</table>